Skip to main content
logo
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.240
-0.070 (-5.34%)
At close: Sep 11, 2026, 4:00 PM EDT
1.220
-0.020 (-1.61%)
After-hours: Sep 11, 2026, 8:00 PM EDT

Calidi Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.050.45
Revenue Growth
-----89.98%-
Gross Profit
----0.030.36
Operating Income
-17.85-20.24-21.78-28.99-23.13-9.61
Net Income
-23.46-25.58-23.81-29.22-25.43-10.93
Earnings Per Share
-33.30-95.13-571.24---1063.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
4.075.69.591.950.372.14
Total Debt
1.942.567.047.245.995.18
Net Cash (Debt)
2.133.042.56-5.29-5.62-3.04
Net Cash Growth
67.90%18.83%----
Net Cash Per Share
3.0211.2961.29---295.96

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-17.75-21.29-19.69-26.98-13.21-7.77
Capital Expenditures
-0.09-0.12-0.02-0.59-0.43-0.21
Free Cash Flow
-17.85-21.41-19.71-27.57-13.64-7.98
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----68.89%79.06%
Operating Margin
-----51395.56%-2139.42%
Pretax Margin
-----56480.00%-2432.52%
Profit Margin
-----56504.44%-2434.97%
FCF Margin
-----30315.56%-1777.28%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----2232.17628.13